SAN ANTONIO, TX – December 12, 2023 – A landmark study, the first phase of the Women Informed to Screen Depending On Measures of Risk (WISDOM) study, has delivered compelling evidence suggesting that a personalized, risk-based approach to breast cancer screening is not only safer and more effective but also holds the potential to revolutionize clinical practice. Published today in the prestigious journal JAMA and presented concurrently at the San Antonio Breast Cancer Symposium, these findings advocate for a significant departure from the traditional "one-size-fits-all" annual mammogram, proposing a system tailored to a woman’s individual risk profile.
This pioneering research indicates that by aligning screening frequency and methodology with personal risk levels – encompassing genetic, biological, and lifestyle factors – healthcare providers can more effectively detect cancers, reduce the likelihood of advanced diagnoses, and ensure optimal screening without over- or under-testing. The study’s initial phase, involving data from 46,000 women across the United States, marks a pivotal moment in the ongoing quest to refine breast cancer detection and prevention strategies.
The Imperative for a Paradigm Shift: Beyond Age-Based Rules
For decades, breast cancer screening guidelines have largely relied on a woman’s age as the primary determinant for initiating and continuing mammography. This approach, while foundational, has increasingly faced scrutiny as scientific understanding of cancer risk has evolved. The assumption that most women face a similar risk, irrespective of their unique biological and lifestyle contexts, has proven to be an oversimplification. Breast cancer remains the most commonly diagnosed cancer among women in the United States, excluding skin cancers, and its variability in incidence and progression underscores the need for a more nuanced strategy.
"These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," asserted Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author. Dr. Esserman emphasized the holistic nature of the proposed approach: "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies." Her statement highlights a critical shift from reactive detection to proactive, individualized risk management.
The limitations of age-based screening are manifold. It can lead to over-screening in low-risk younger women, exposing them to unnecessary radiation and the anxiety of false positives. Conversely, it risks under-screening high-risk younger women who might benefit from earlier, more intensive surveillance. The WISDOM study directly addresses these inefficiencies by proposing a framework that intelligently allocates resources and interventions based on a comprehensive understanding of individual susceptibility.
Chronology and Rigorous Methodology of the WISDOM Study
The WISDOM study, with UCSF serving as its coordinating center, embarked on its ambitious journey in 2016. Its primary objective was to rigorously compare the efficacy and safety of traditional annual mammography against a dynamic, individualized screening strategy. This multi-institutional endeavor, supported by significant funding from the Patient-Centered Outcomes Research Institute, the National Cancer Institute, and the Breast Cancer Research Foundation, represents a collaborative effort involving numerous academic and clinical institutions across the U.S. and internationally.
The Study’s Design:
At the heart of the WISDOM methodology was the application of well-validated risk models to categorize participants into four distinct groups. This categorization went far beyond chronological age, incorporating a sophisticated array of data points:
- Age: While not the sole factor, age remained a component in risk calculation.
- Genetic Information: This included testing for known pathogenic variants like BRCA1 and BRCA2, as well as the innovative use of polygenic risk scores (PRS).
- Lifestyle Factors: Data on diet, physical activity, alcohol consumption, and other behavioral elements.
- Health History: Personal and family history of breast cancer, benign breast conditions, and other relevant medical conditions.
- Breast Density: A known independent risk factor for breast cancer.
By integrating these diverse factors, researchers created a more precise and predictive risk assessment for each woman.
Tailored Screening Recommendations:
Based on their assigned risk categories, participants received customized screening advice:
- Lowest Risk Group (26% of participants): These women were advised to delay routine screening until age 50, or until an algorithm indicated their risk had naturally escalated to that of a typical 50-year-old. This recommendation aims to minimize unnecessary screenings in a population with very low probability of developing early-onset cancer.
- Average Risk Group (62% of participants): The majority of women fell into this category, for whom biennial (every two years) mammograms were recommended. This aligns with certain existing guidelines but is now grounded in a more data-driven risk assessment.
- Elevated Risk Group (8% of participants): Women in this group were advised to undergo annual mammograms, reflecting their increased susceptibility to the disease.
- Highest Risk Group (2% of participants): This cohort faced the most intensive screening protocol, receiving mammograms twice a year, alternating with MRI scans, regardless of their age. This aggressive approach is designed to catch aggressive cancers early in individuals with significantly heightened risk.
Supporting Data and Transformative Findings
The WISDOM study’s initial phase yielded several critical insights that underscore the potential of personalized screening:
1. Equivalent Safety and Enhanced Efficiency:
Crucially, the personalized screening approach did not lead to a higher rate of late-stage cancer diagnoses compared to traditional screening. This finding provides robust evidence that tailoring screening is not only effective but can maintain, if not improve, diagnostic outcomes. It challenges the assumption that less frequent screening for lower-risk women would inevitably lead to missed or advanced cancers.
Co-author Jeffrey A. Tice, MD, a UCSF professor of Medicine specializing in breast cancer risk assessment tools, highlighted the practical implications: "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer." This reallocation of resources promises not only better patient outcomes but also a more sustainable and economically sensible healthcare system.
2. Overwhelming Patient Acceptance:
A compelling indicator of the personalized approach’s viability came from participants who opted out of the randomized trial arm and instead joined an observational group. A remarkable 89% of these women chose to adopt the risk-based screening strategy, demonstrating strong confidence and acceptance among the patient population for this innovative model. This high acceptance rate suggests that women are eager for more precise, individualized health guidance.
3. Unmasking "Hidden" Genetic Risks:
One of the most profound revelations of the WISDOM study pertains to genetic testing. Researchers included women as young as 30 to identify those at increased risk for aggressive early cancers due to inherited genetic variants. A staggering 30% of women who tested positive for a genetic variant linked to higher breast cancer risk reported no family history of the disease. Under current clinical guidelines, many of these women would not typically qualify for genetic testing, remaining unaware of their elevated risk until a diagnosis occurred.
This finding fundamentally challenges existing genetic testing criteria, which heavily rely on family history. It underscores the urgent need to expand access to genetic screening to a broader population, moving away from a reactive model to a proactive, population-based approach.
4. The Power of Polygenic Risk Scores (PRS):
Beyond well-known pathogenic variants like BRCA1 and BRCA2, the study also evaluated smaller DNA changes that, when combined, form a polygenic risk score (PRS). This sophisticated genetic tool significantly improved the precision of risk predictions. The integration of PRS resulted in 12% to 14% of participants being reassigned to a different risk category, demonstrating its power to fine-tune individual risk assessment and subsequently, screening recommendations.
"This is one of the first studies to offer genetic testing to all women, regardless of family history," noted co-author Allison S. Fiscalini, MPH, of UCSF, director of the Athena Breast Health Network and the WISDOM study. "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention."
5. Personalized Prevention Strategies:
The WISDOM study extended beyond just screening, offering customized guidance on lowering cancer risk for participants identified as having elevated or highest risk. This included access to an online decision-making tool focused on breast health, direct contact with a breast health specialist, and recommendations covering lifestyle changes (e.g., improving diet, increasing physical activity). Discussions about medications known to reduce risk were also initiated, empowering women with actionable steps to mitigate their personal risk. This comprehensive approach embodies the spirit of personalized medicine, moving beyond mere detection to proactive prevention.
Official Responses and Expert Endorsements
The publication of the WISDOM study results has generated significant anticipation within the medical community, with lead researchers articulating a clear vision for its impact.
Dr. Laura Esserman’s call for a transformation of clinical guidelines resonates deeply within the oncology community. Her extensive experience as a breast care center director lends substantial weight to her assertion that the traditional age-based model is outdated. She envisions a future where risk assessment is the cornerstone of personalized health, enabling physicians to move beyond generalized recommendations to truly individualized care plans. This proactive stance, she argues, is essential for improving public health outcomes related to breast cancer.
Dr. Jeffrey Tice’s emphasis on efficiency speaks to the pragmatic considerations of healthcare delivery. In an era of increasing healthcare costs and resource constraints, optimizing screening protocols means not only better patient care but also a more sustainable system. By directing intensive screening and preventive resources to those who need them most, the system can avoid unnecessary interventions in low-risk individuals, freeing up capacity for critical care elsewhere.
Allison Fiscalini’s comments highlight the inclusivity and democratic potential of the WISDOM approach, particularly concerning genetic testing. The revelation that a significant percentage of women with high-risk genetic variants lack a family history underscores a critical blind spot in current medical practice. Her vision of genetic testing as a routine component of comprehensive risk assessment promises to identify and protect a previously unrecognized population at elevated risk, thereby significantly improving the safety and effectiveness of prevention efforts on a population scale.
Implications and the Future of Breast Cancer Screening
The findings of the WISDOM study carry profound implications for women’s health, healthcare policy, and the future of medical practice:
1. Reshaping Clinical Guidelines: The immediate and most significant implication is the potential for national and international clinical guidelines to be rewritten. Organizations like the American Cancer Society, the U.S. Preventive Services Task Force, and other leading medical bodies will need to critically evaluate these findings and consider incorporating personalized risk assessment into their recommendations. This would mark a pivotal shift in how breast cancer screening is approached globally.
2. Enhanced Patient Safety and Efficacy: By reducing unnecessary mammograms for low-risk women, the personalized approach minimizes exposure to radiation and the psychological burden of false positives, which can lead to anxiety, biopsies, and further testing. Simultaneously, it ensures that high-risk women receive the intensive surveillance they need, potentially catching aggressive cancers at earlier, more treatable stages. This dual benefit of reducing harm while increasing efficacy represents a significant advance.
3. Economic and Resource Optimization: The strategic reallocation of resources from lower-risk to higher-risk populations could lead to substantial cost savings within the healthcare system. Fewer unnecessary screenings, biopsies, and follow-up procedures for low-risk individuals can free up funds and personnel to focus on targeted prevention and early intervention for those truly in need. This efficiency will be critical in managing the escalating costs of cancer care.
4. Empowering Women Through Knowledge: Providing women with a comprehensive understanding of their individual breast cancer risk empowers them to make informed decisions about their health. Access to genetic information, lifestyle guidance, and personalized screening schedules fosters a proactive approach to health management, moving beyond passive adherence to generalized recommendations.
5. Broadening Genetic Testing Access: The study’s compelling evidence that a significant portion of women with high-risk genetic variants have no family history will likely spur calls for broader, potentially population-based, genetic testing. This expansion would necessitate addressing issues of cost, access, and genetic counseling infrastructure, but the long-term benefits of identifying at-risk individuals earlier could be immense.
6. The Evolution of Risk Assessment Tools: The successful integration of polygenic risk scores highlights the ongoing evolution of risk assessment. Future research will likely focus on refining these tools further, incorporating new biomarkers and AI-driven predictive analytics to achieve even greater precision in identifying at-risk individuals.
7. Addressing Implementation Challenges: While the promise is significant, the transition to a personalized screening model will not be without challenges. These include educating both clinicians and the public about the new approach, ensuring equitable access to comprehensive risk assessment tools and genetic testing across diverse populations, developing standardized protocols for implementing risk-based screening, and training healthcare professionals in genetic counseling and personalized prevention strategies.
What Comes Next: WISDOM 2.0
Researchers are not resting on these initial findings. The WISDOM 2.0 study is already underway and actively enrolling participants, with the goal of further refining risk assessment models. This next phase aims to better identify women who face a higher likelihood of developing aggressive breast cancers, ensuring they receive screening and prevention strategies precisely tailored to their long-term health needs. The continuous evolution of this research underscores the commitment to optimizing breast cancer care for every woman.
The WISDOM study represents more than just new data; it embodies a philosophical shift in medicine—one that recognizes and responds to the unique biological individuality of each patient. As its findings begin to permeate clinical guidelines and practice, it holds the potential to usher in an era where breast cancer screening is not just routine, but truly personalized, proactive, and powerfully effective.
Co-Authors and Funding details, as per the original article, include a broad network of investigators from UCSF, UC Los Angeles, UC Irvine, UC San Diego, San Francisco VA Health Care System, Sanford Health in North Dakota, University of Chicago, Diagnostic Center of Miami, University of Alabama, Virginia Commonwealth University, Weill Cornell Medicine in New York, and the Karolinska Institutet in Stockholm. Funding support included the Patient-Centered Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation, among others. Conflicts of Interest were disclosed in the published paper.
About the Author
